Symposium Agenda
The symposium is for students, trainees, active researchers, clinicians and those who may not presently be engaged directly in HIV research. It will feature leading scientists and clinicians describing the current state of the art in HIV/AIDS research and clinical care, highlighting recent progress in key areas, remaining major challenges, and approaches to overcome those challenges.
The meeting is intended to place emphasis on aspects of HIV research with the potential to impact clinical care and vaccine design. The scope of the meeting will extend to KSHV, as well.
Agenda
*Agenda subject to change
Reception, 5:30-7 p.m.
Whitaker Campus Commons
Welcome & Introductions, 7 p.m.
Hodson Auditorium, Rosenstock Hall
- Debbie Ricker, Ph.D.
Interim President, Hood College - Ethan Dmitrovsky, M.D.
Director, Frederick National Laboratory for Cancer Research
Keynote, 7:30 p.m.
"Reaching the 2030 SDG Target for AIDS: Success, Challenges and Prospects"
Salim S. Abdool Karim, Ph.D.
Director, Centre for AIDS Program of Research, South Africa (CAPRISA)
CAPRISA Professor of Global Health, Columbia University
Special Advisor to the Director-General of the World Health Organization
Pro Vice-Chancellor (Research), University of KwaZulu-Natal
Adjunct Professor of Medicine, Weill Medical College of Cornell University
Session 1: Epidemiology of HIV Disease
- 7:30-8 a.m., Networking
Continental breakfast will be provided. - 8-8:15 a.m., Introduction
Douglas Lowy, Principal Deputy Director, National Cancer Institute - 8:15-9 a.m., HIV: History, Current Status, Future Challenges and Strategies
Speaker TBD
Session 2: Vaccine Prevention
- 9:05-9:30 a.m., Modeling and Computational Approaches to Next Generation Vaccine Design for T-Cell and Antibody Responses
Arup K. Chakraborty, John M. Deutch Institute Professor, Professor Chemical Engineering, Physics and Chemistry
Massachusetts Institute of Technology - 9:35-10 a.m., T-Cell Vaccines Targeting Conserved, Constrained Epitopes
Gaurav D. Gaiha, Principal Investigator and Group Leader, Ragon Institute of MGH, MIT and Harvard - 10:05-10:15 a.m., Break
- 10:15-10:40 a.m., Efficacy and Mechanisms of Unconventionally Restricted CMV-Vectored T-Cell Vaccines
Louis J. Picker, Professor, VGTI-Vaccine and Gene Therapy Institute, Molecular Microbiology and Immunology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine, Oregon Health & Science University - 10:45-11:10 a.m., HIV Vaccine Immunogen Design for Induction of Broadly Neutralizing Antibodies
William Schief, Professor, Department of Immunology and Microbiology, Scripps Research Institute - 11:15-11:40 a.m., Application of Systems Immunology to Improve Vaccines
Bali Pulendran, Violetta L. Horton Professor, Stanford University School of Medicine - 11:45 a.m.-12:10 p.m., Improving Efficacy with Alternative Vaccine Delivery Approaches
Darrell Irvine, Underwood-Prescott Professor, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology - 12:15-1:30 p.m., Lunch
Session 3: Non-Vaccine Prevention: bNAbs and Long-Acting Anti-Retrovirals
- 1:30-1:55 p.m., How do Antibodies Protect Against HIV
Dennis Burton, Chair and Professor, Department of Immunology and Microbiology, Scripps Research Institute, Director, AIDS Vaccine Research IAVI Neutralizing Antibody Center - 2-2:25 p.m., Lifelong Delivery of Monoclonal Antibodies AAV Vectors
Ronald Desrosiers, Professor and Vice Chair, Department of Pathology, University of Miami Miller School of Medicine - 2:30-2:55 p.m., Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis: State of the Science, Implementation and Looking to the Future
Raphael J. Landovitz, Professor of Medicine, Interim Chief, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Director, UCLA Center for Clinical AIDS Research & Education, Co-Director Center for HIV Identification, Prevention, and Treatment Services - 2:55-3:10 p.m., Break
- 3:10-3:35 p.m., Preclinical Evaluations of Long-acting Lenacapavir PrEP in Nonhuman Primates Challenged with Simian-tropic HIV-1
Gregory Del Prete, Associate Director for Nonhuman Primate Resources, Principal Investigator, Viral Persistence Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research - 3:40-4:05 p.m., Advancements in Clinical Development of Lenacapavir
Laurie VanderVeen, Director, HIV Clinical Virology, Gilead Sciences - 6 p.m., Speaker/Panelist Dinner
Location TBD (Hood College)
Session 4: Treatment of HIV Infection: State of the ART
- 7:30-8 a.m., Networking
Continental breakfast will be provided - 8:05-8:25 a.m., PEPFAR at 20
Nelson L. Michael, Director, Center for Infectious Disease Research, Walter Reed Army Institute of Research - 8:30-8:55 a.m., Experience with Roll Out of Modern ART in an Upper Middle-Income Country
Gustavo Reyes Terán, Head of the Coordinating Commission, National Health Institutes and High Specialty Hospitals, Mexico - 9-9:25 a.m., Current Status and Challenges in Treatment of HIV Infection
Steven Deeks, Professor of Medicine, University of California San Francisco, Faculty Member, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital - 9:30-9:55 a.m., Chronic Inflammation and Other Co-Morbidities in Treated HIV Infection
Peter W. Hunt, Professor of Medicine, University of California San Francisco Associate Chief for Research, ZSFG-UCSF Department of Medicine, Department of Medicine, Division of Experimental Medicine - 9:55-10:10 a.m., Break
Session 5: CNS Infection in HIV; KSHV
- 10:10-10:35 a.m., CNS Infection with HIV
Sarah Joseph, Assistant Professor, University of North Carolina School of Medicine, Microbiology and Immunology - 10:40-11:05 a.m., KSHV Virology and Epidemiology
Elizabeth Yu Chiao, M.D., MPH, Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX - 11:10-11:35 a.m., Insights on the Pathogenesis and Treatment of KSHV-Associated Tumors and Other Diseases
Robert Yarchoan, Chief, HIV and AIDS Malignancy Branch, Center for Cancer Research, Director, Office of HIV and AIDS Malignancy, National Cancer Institute - 11:40 a.m.-12:05 p.m., KSHV PDX Models to Guide Treatment
Laurie T. Krug, Stadtman Investigator, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute - 12:05-1:30 p.m., Lunch
Session 6: HIV Rebound Competent Viral Reservoir and Towards a Cure
- 1:30-1:55 p.m., Molecular Aspects of the HIV Reservoir
Xu Yu, Associate Professor of Medicine, Harvard Medical School, Physician Investigator, Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Associate Immunologist, Brigham and Woman's Hospital - 2-2:25 p.m., Towards an HIV Cure: Novel Approaches to Reduce and Control the HIV Reservoir
Sharon Lewin, Director, The Peter Doherty Institute for Infection and Immunity, Professor of Medicine, The University of Melbourne - 2:30-2:55 p.m., Gene Therapy for HIV Infection
Hans-Peter Kiem, Deputy Director, Translational Science and therapeutics Division, Professor, Vaccine and Infectious Disease Division - 3-3:15 p.m., Break
- 3:15-4:15 p.m., Panel Discussion: Moderator - John Mellors, MD, Department of Medicine, University of Pittsburgh
- Mike McCune, Head, HIV Frontiers, Bill & Melinda Gates Foundation
- Mike Saag, Professor of Medicine-Infectious Diseases, University of Alabama at Birmingham
- Daria Hazuda, Head of Infectious Diseases and Vaccine Research, Generate Biomedicines (former VP of Infectious Diseases and Vaccines and Chief Scientific Officer, Merck Cambridge Research)
- Lynda Dee, Community Engagement Coordinator DARE MDC AIDS Action Baltimore, Executive Director
- John Coffin, Tufts University School of Medicine
- 4:15 p.m., Closing Remarks (meeting summary, vision for the future of HIV)
- Jeff Lifson, Director, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
- Mary Carrington, Director, Basic Science Program, Frederick National Laboratory for Cancer Research
Are you ready to say Hello?
Choose a Pathway
Information will vary based on program level. Select a path to find the information you're looking for!